Hypogonadism and its treatment following ischaemic stroke in men with type 2 diabetes mellitus

References

• Vereshchagin NV, Varakin YY. Epidemiology of stroke in Russia: results and epidemiological aspects of the problem. Stroke. Supplement to: Korsakov J Neurol Psychiatry 2001;1:34–40.
   Google Scholar
• Skoromets TP, Skoromets AA, Skoromets TA. Neural diseases. Moscow: Medpress-inform 2010; 2010. p. 552.
   Google Scholar
• Rosamund W, et al. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee 2008;146.
   Google Scholar
• Shevchenko OP, Praskurnichii EA, Yakhno NN, et al. Arterial hypertension and cerebral stroke. Moscow: Reafarm; 2001. p. 192.
   Google Scholar
• Sullivan JM, Fowlkes LP. The clinical aspects of estrogen and the cardiovascular system. Obstet Gynocol. 1996;87:36S–343.
   PubMed Web of Science ®Google Scholar
• Morley JE, Charlton E, Patrick P, et al. Validation of screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49:1239–1242.
   PubMed Web of Science ®Google Scholar
• Corona G, Forti G, Maggi M. Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. Aging Male. 2008;11:193–199.
   PubMed Web of Science ®Google Scholar
• Mazur A, Westerman R, Werdecker A, et al. Testosterone and type 2 diabetes in men. Aging Male. 2014;17:18–24.
   PubMed Web of Science ®Google Scholar
• Dedov II, Kalinchenko SY. Age-related androgen deficiency in men. Moscow: Prakticheskaya Meditsina; 2006. p. 239.
   Google Scholar
• Vertkin AL, Morgunov LY, Arinina EN, et al. Testosterone deficiency and somatic disease. Lechashchii Vrach (Practitioner). 2006;10:34–38.
   Google Scholar
• Schipf S, Haring R, Friedrich N, et al. Low total testosterone is associated with increased risk of incident type 2 diabetes mellitus in men: results from the Study of Health in Pomerania (SHIP). Aging Male 2011;14:168–175.
   PubMed Web of Science ®Google Scholar
• Almehmadi Y, Yassin DJ, Yassin AA. Erectile dysfunction is a prognostic indicator of comorbidities in men with late onset hypogonadism. Aging Male. 2015;18:186–194.
   PubMed Web of Science ®Google Scholar
• Rabijewski M, Papierska L, Piątkiewicz P. The prevalence of prediabetes in population of Polish men with late-onset hypogonadism. Aging Male. 2014;17:141–146.
   PubMed Web of Science ®Google Scholar
• Haidar A, Yassin A, Saad F, et al. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male. 2007;10:189–196.
   PubMed Web of Science ®Google Scholar
• Saad F, Yassin A, Almehmadi Y, et al. Effects of long-term testosterone replacement therapy, with a temporary intermission, on glycemic control of nine hypogonadal men with type 1 diabetes mellitus – a series of case reports. Aging Male. 2015;18:164.
   PubMed Web of Science ®Google Scholar
• Yassin AA, Saad F, Haider A, et al. The role of the urologist in the prevention and early detection of cardiovascular disease. Arab J Urol. 2011;9:57–62.
   PubMedGoogle Scholar
• Ho CH, Wu CC, Chen KC, et al. Erectile dysfunction, loss of libido and low sexual frequency increase the risk of cardiovascular disease in men with low testosterone. Aging Male. 2016;19:96–101.
   PubMed Web of Science ®Google Scholar
• Leoni LA, Fukushima AR, Rocha LY, et al. Physical activity on endothelial and erectile dysfunction: a literature review. Aging Male. 2014;17:125–130.
   PubMed Web of Science ®Google Scholar
• Smith ML, Honoré Goltz H, Ahn S, et al. Correlates of chronic disease and patient-provider discussions among middle-aged and older adult males: implications for successful aging and sexuality. Aging Male. 2012;15:115–123.
   PubMed Web of Science ®Google Scholar
• Morgunov LIu, Denisova IA, Rozhkova TI, et al. Androgenic deficit and its treatment in stroke male patients with diabetes mellitus type II. Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111:21–24.
   PubMedGoogle Scholar
• Amos AF, McCathy DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14:1–85.
   PubMed Web of Science ®Google Scholar
• Dedov II, Mel’nichenko GA, Fadeev VV. Endocrinology. Moscow: Geotar-Media; 2008. p. 432.
   Google Scholar
• Svartberg J, Midtby M, Bønaa KH, et al. The associations of lifestyle factors and chronic disease with testosterone in men. The Tromsø Study. Eur J Endocrinol. 2003;149:145–152.
   PubMed Web of Science ®Google Scholar
• Dockery F, Bulpitt CJ, Donaldson M, et al. The relationship between androgens and arterial stiffness in older men. J Am Geriatr Soc. 2003;51:1627–1632.
   PubMed Web of Science ®Google Scholar
• Taggart H, Sheridan B, Stout RW. Sex hormone levels in younger male stroke survivors. Atherosclerosis. 1980;35:123–125.
   PubMed Web of Science ®Google Scholar
• Goncharov NP, Katsiya GV, Dobracheva AD, et al. Androgen deficiency and problems in its diagnosis using current non-isotopic methods for determining testosterone. Problemy Endokrinoklogii (Problems in Endocrinology). 2008;54:30–39.
   Google Scholar
• Goncharov NP, Katsiya GV. Current methods for determining testosterone. problems and their solution. Andrologiya i Genital’naya Khirurgiya (Andrology and Genital Surgery). 2008;2:27–37.
   Google Scholar
• Dash RJ, Sethi BK, Nalini K, et al. Circulating testosterone in pure motor stroke. Funct Neurol. 1991;6:29–34.
   PubMedGoogle Scholar
• Jeppesen LL1, Jørgensen HS, Nakayama H, et al. Decreased serum testosterone in men with acute ischeamic stroke. Arterioscler Thromb Vasc Biol. 1996;16:749–754.
   PubMed Web of Science ®Google Scholar
• Gatson JW, Singh M. Activation of a membrane-associated androgen receptor promotes cell death in primary cortical astrocytes. Endocrinology. 2007;148:2458–2464.
   PubMed Web of Science ®Google Scholar
• Pan Y, Zhang H, Acharya AB, et al. Effect of testosterone on functional recovery in a castrate male rat stroke model. Brain Res. 2005;1043:195–204.
   PubMed Web of Science ®Google Scholar
• Sheilor IM, Zilov AV. Possible ways of using testosterone to correct metabolic syndrome and obesity in men. Consilium Medicum. 2007;9:71–74.
   Google Scholar
• Traish AM, Haider A, Haider KS, et al. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (control) groups. J Cardiovasc Pharmacol Therap. 2017;22:414–433.
   PubMed Web of Science ®Google Scholar
• Abbasi A, Mattson DE, Cuisinier M, et al. Hyposomatomedinemia and hypogonadism in hemiplegic men who live in nursing homes. Arch Phys Med Rehabil. 1994;75:594–599.
   PubMed Web of Science ®Google Scholar
• Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. 2003;24:313–340.
   PubMed Web of Science ®Google Scholar
• Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev. 2003;24:183–217.
   PubMed Web of Science ®Google Scholar
• Pongkan W, Chattipakorn SC, Chattipakorn N. Roles of testosterone replacement in cardiac ischemia-reperfusion injury. J Cardiovasc Pharmacol Ther. 2016;21:27–43.
   PubMed Web of Science ®Google Scholar
• Srinath R, Gottesman RF, Hill Golden S, et al. Association between endogenous testosterone and cerebrovascular disease in the ARIC study (Atherosclerosis Risk in Communities). Stroke. 2016;47:2682–2688.
   PubMed Web of Science ®Google Scholar
• Bertoluci MC, Rocha VZ. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr. 2017;9:25.
   PubMed Web of Science ®Google Scholar
• Yassin AA, Nettleship J, Almehmadi Y, et al. Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study. Andrologia. 2016;48:793–799.
   PubMed Web of Science ®Google Scholar
• Haider A, Yassin A, Doros G, et al. Effects of long-term testosterone therapy on patients with "diabesity”: results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol. 2014;2014:683515.
   PubMed Web of Science ®Google Scholar
• Conaglen HM, Paul RG, Yarndley T, et al. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice. J Sex Med. 2014;11:574–582.
   PubMed Web of Science ®Google Scholar
• Tan WS, Low WY, Ng CJ, et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU Int. 2013;111:1130–1140.
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med. 2010;7:3495–3503.
   PubMed Web of Science ®Google Scholar
• Momosaki R, Abo M, Watanabe S, et al. Effects of testosterone levels on functional recovery with rehabilitation in stroke patients. Neurol Med Chir (Tokyo). 2014;54:794–798.
   PubMed Web of Science ®Google Scholar
• Webb CM, Elkington AG, Kraidly MM, et al. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol. 2008;101:618–624.
   PubMed Web of Science ®Google Scholar
• Haider A, Yassin A, Haider KS, et al. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study. Vasc Health Risk Manag. 2016;14:251–261.
   Google Scholar
• Cheetham TC, An J, Jacobsen SJ, et al. Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency. JAMA Intern Med. 2017;177:491–499.
   PubMed Web of Science ®Google Scholar
• Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36:2706–2715.
   PubMed Web of Science ®Google Scholar
• Anderson JL, May HT, Lappé DL, et al. Impact of testosterone replacement therapy on myocardial infarction, stroke, and death in men with low testosterone concentrations in an integrated health care system. Am J Cardiol. 2016;117:794–799.
   PubMed Web of Science ®Google Scholar
• English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000;102:1906–1911.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90:871–876.
   PubMed Web of Science ®Google Scholar
• Rosano GM, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99:1666–1670.
   PubMed Web of Science ®Google Scholar
• Mathur A, Malkin C, Saeed B, et al. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol. 2009;161:443–449.
   PubMed Web of Science ®Google Scholar
• Webb CM, Adamson DL, de, et al. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol. 1999;83:437–439.
   PubMed Web of Science ®Google Scholar
• Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6:1–7.
   PubMedGoogle Scholar
• Salman M, Yassin DJ, Shoukfeh H, et al. Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy. Aging Male. 2017;20:45–48.
   PubMed Web of Science ®Google Scholar
• Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829–1836.
   PubMed Web of Science ®Google Scholar
• Corona G, Dicuio M, Rastrelli G, et al. Testosterone treatment and cardiovascular and venous thromboembolism risk: what is 'new'? J Investig Med. 2017;65:964–973.
   PubMed Web of Science ®Google Scholar
• Kelly DM, Jones TH. Testosterone and cardiovascular risk in men. Front Horm Res. 2014;43:1–20.
   PubMed Web of Science ®Google Scholar
• Webb CM, Collins P. Testosterone and coronary artery disease in men. Maturitas. 2010;67:15–19.
   PubMed Web of Science ®Google Scholar
• Akishita M, Hashimoto M, Ohike Y, et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res. 2007;30:1029–1034.
   PubMed Web of Science ®Google Scholar
• Kang SM, Jang Y, Kim Ji, et al. Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol. 2002;89:862–864.
   PubMed Web of Science ®Google Scholar
• Bowles DK, Maddali KK, Ganjam VK, et al. Endogenous testosterone increases L-type Ca2+ channel expression in porcine coronary smooth muscle. Am J Physiol Heart Circ Physiol. 2004;287:H2091–H2098.
   PubMed Web of Science ®Google Scholar
• Gonzales RJ, Krause DN, Duckles SP. Testosterone suppresses endothelium-dependent dilation of rat middle cerebral arteries. Am J Physiol Heart Circ Physiol. 2004;286:H552–H560.
   PubMed Web of Science ®Google Scholar
• Cornoldi A, Caminiti G, Marazzi G, et al. Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. Int J Cardiol. 2010;142:50–55.
   PubMed Web of Science ®Google Scholar
• Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 1994;14:701–706.
   PubMed Web of Science ®Google Scholar
• Nathan L, Shi W, Dinh H, et al. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci USA. 2001;98:3589–3593.
   PubMed Web of Science ®Google Scholar
• Hatakeyama H, Nishizawa M, Nakagawa A, et al. Testosterone inhibits tumor necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in human aortic endothelial cells. FEBS Lett. 2002;530:129–132.
   PubMed Web of Science ®Google Scholar
• Quillinan N, Deng G, Grewal H, et al. Androgens and stroke: good, bad or indifferent? Exp Neurol. 2014;259:10–15.
   PubMed Web of Science ®Google Scholar
• Soisson V, Brailly-Tabard S, Helmer C, et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study. Maturitas. 2013;75:282–288.
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19:64–69.
   PubMed Web of Science ®Google Scholar